An improved clinical model to predict stimulated C-peptide in children with recent-onset type 1 diabetes.

What Was Tested

This clinical trial looks at C-Peptide.

Stimulated C-peptide measurement after a mixed meal tolerance test (MMTT) is the accepted gold standard for assessing residual beta-cell function in type 1 diabetes (T1D); however, this approach is impractical outside of clinical trials.

Who Took Part

The age groups tagged for this paper are children, teenagers, young adults and adults, both men and women.

A clinical model to predict 90-minute MMTT stimulated C-peptide in children with recent-onset T1D was developed from the combined AbATE, START, and TIDAL placebo subjects (n = 46) 6 months post-recruitment using multiple linear regression.

How the Study Was Run

In design terms this was a placebo-controlled study.

The comparison arm used a placebo, so changes seen with C-Peptide could be set against what happens without it.

This model was then validated in a clinical cohort (Hvidoere study group, n = 262).

What Was Measured

Stimulated C-peptide measurement after a mixed meal tolerance test (MMTT) is the accepted gold standard for assessing residual beta-cell function in type 1 diabetes (T1D); however, this approach is impractical outside of clinical trials.

The subject headings attached to it are Age of Onset, Antibodies, Monoclonal, Humanized, C-Peptide, Cohort Studies, Diabetes Mellitus, Type 1, Insulin Secretion and Insulin-Secreting Cells.

Author keywords: beta cell function, partial remission and type 1 diabetes.

What This Means in Plain Language

The paper is a placebo-controlled study of C-Peptide.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2019 (Pediatric diabetes), a journal based in China.

More context: the C-Peptide compound page, all human trials.